<DOC>
	<DOCNO>NCT00544648</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Nab-paclitaxel ( paclitaxel albumin-stabilized nanoparticle formulation ) may make tumor cell sensitive radiation therapy . Giving nab-paclitaxel together radiation therapy carboplatin may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose give nab-paclitaxel together carboplatin radiation therapy see well work treat patient stage III non-small-cell lung cancer remove surgery .</brief_summary>
	<brief_title>Ph I/II Nab-Paclitaxel &amp; Carboplatin w/Concurrent Radiation Therapy Unresectable Stg III NSCLC</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose nab-paclitaxel combine concurrently carboplatin radiation follow two course nab-paclitaxel carboplatin consolidation . ( Phase I ) - To evaluate progression-free survival patient stage III unresectable non-small cell lung cancer treat nab-paclitaxel , carboplatin , radiotherapy follow two course nab-paclitaxel carboplatin consolidation . ( Phase II ) Secondary - To assess safety tolerability identify dose-limiting toxicity patient receive nab-paclitaxel combine concurrently carboplatin radiotherapy . ( Phase I ) - To assess progression-free survival , response rate , survival . ( Phase I ) - To assess overall survival response rate patient treat study . ( Phase II ) - To assess safety tolerability patient receive nab-paclitaxel combine concurrently carboplatin radiotherapy follow two course nab-paclitaxel/carboplatin consolidation . ( Phase II ) OUTLINE : This multicenter study . - Phase I : - Concurrent chemoradiotherapy : Patients receive escalate dos nab-paclitaxel IV 30 minute carboplatin IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 , 43 . They also receive conformal radiotherapy daily 5 day week day 1-5 week 1-7 . Patients evaluated week 8-10 . Patients disease progression remove study . Patients stable disease , partial response , complete response proceed consolidation chemotherapy 3 week completion chemoradiotherapy . - Consolidation chemotherapy : Patients receive nab-paclitaxel IV 30 minute day 1 , 8 , 15 carboplatin IV 30 minute day 1 . Treatment repeat ever 21 day 2 course . - Phase II : Patients receive concurrent chemoradiotherapy Maximum Tolerated Dose ( MTD ) nab-paclitaxel follow consolidation chemotherapy phase I . After completion study treatment , patient follow 2 month , every 3 month 2 year , every 4 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 98 patient ( 15 patient phase I 83 patient phase II ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion Criteria Phase I Phase II Patients : Patients must voluntarily sign date inform consent initiation study procedures Patients must nonmetastatic , inoperable , Stage IIIA IIIB histologically cytologically document NSCLC without evidence malignant pleural effusion Patients must receive prior systemic chemotherapy , thoracic radiotherapy surgical resection treatment NSCLC Patients must least one site unidirectionally measurable disease define Response Evaluation Solid Tumors ( RECIST ) criterion Patients must ≥ 3 week formal exploratory thoracotomy Patients must Radiation Oncology Medical Oncology consult approval prior study entry Patients must ≥ 18 year age Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Women childbearing potential must negative baseline serum pregnancy negative urine pregnancy test within 7 day prior Week 1 , Day 1 must breast feeding . Women childbearing potential men sexual partner child bear potential must use effective method contraception begin prior study entry , duration study participation minimum 3 month last dose chemotherapy . Patients must adequate hepatic , renal , lung bone marrow function define : Absolute neutrophil count ( ANC ) ≥1,500/mm3 Hemoglobin ≥ 9.0 gm/dL Serum Creatinine ≤1.5mg/dl Platelets &gt; 100,000/mm3 Total bilirubin ≤ upper limit normal AST ALT &lt; 2.5 X upper limit normal Alkaline phosphatase &lt; 2.5 X upper limit normal Calculated CrCl &gt; 45 ml/min ( via CockroftGault formula ) Forced expiratory volume 1 second ( FEV 1 ) &gt; 800 ml Exclusion Criteria Phase I Phase II Patients : Known hypersensitivity carboplatin nabpaclitaxel Peripheral neuropathy Grade ≥ 2 Wet stage IIIB ( document malignant pleural effusion ) stage IV NSCLC Previous chemotherapy radiation therapy chest Any concomitant malignancy brain metastasis Any uncontrolled , clinically significant medical psychiatric disorder Pregnant nursing woman A great equal 10 % weight loss past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>